0.500

+0.470 (+1566.67%)
Range 0.260 - 0.510   (96.15%)
Open 0.510
Previous Close 0.030
Buy Price 0.357
Buy Volume -
Sell Price 0.361
Sell Volume -
Volume 5,935
Value -
Remark
Measurement Type Value
EPS (USD) -1.394
Trailing EPS (USD) -1.298
NAV (USD) -0.185
Cash In Hand (USD) 0.115
Dividend -
Dividend Yield (%) -
PE -
Trailing PE -
Price / NAV -0.286
Price / Cash In Hand 0.463
Issued & Paid-up Shares 41,928,000
Treasury Shares -
Market Cap (M) 0.84
Par Value (USD) n.a.
Beta - 75 Days 4.773
R-Squared - 75 Days(%) 2.09
Beta - 500 Days -6.781
R-Squared - 500 Days(%) 0.02
ISIN Code
Under CPF Investment Scheme (CPFIS) No
Index Components
Delayed prices. Updated at 17 Sep 2020 05:20.
Data powered by
View All Events

About IMMUNOCELLULAR THERAPEUTICS LTD

ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is engaged in developing immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors. Immunotherapy is an approach to treat cancer in which a patient�s own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies. The Company�s products include ICT-107, ICT-140, ICT-121, ICT-109 and DIAAD. ICT-107, the pipeline product, is a Phase II therapeutic dendritic cell (DC) vaccine for the treatment of glioblastoma multiforme (GBM), the common and lethal type of brain cancer. ICT-107 is designed to activate a patient�s immune system to target six different tumor-associated antigens. In February 2012, it acquired a world-wide license from the University of Pennsylvania and The John Hopkins University (JHU).

Top Contributors

USNews avatar
275
Followers 218
Posts 1283333
SeekingAlphaRSS avatar
303
Followers 255
Posts 64148

Loading Chart...